Isovaleric Acidemia (IVA) Treatment Market Growth Trends: Moderate Expansion with 5.8% CAGR Until 2029
Get 20% Off All Market Studies With Code ONLINE20 – Anticipate Tariff Impacts, Market Disruptors, and Long-Term Growth Trends
What Is the Expected Market Growth Rate for the Isovaleric Acidemia (IVA) Treatment Market?
The isovaleric acidemia (IVA) treatment market size has grown strongly in recent years. It will grow from $0.6 billion in 2024 to $0.63 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increasing awareness of rare metabolic disorders, a rising number of newborn screening programs, a rise in government funding for orphan diseases, increasing focus on enzyme replacement therapies, and rising demand for early diagnosis and genetic counseling.
The isovaleric acidemia (IVA) treatment market size is expected to see strong growth in the next few years. It will grow to $0.79 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to increasing adoption of gene therapy approaches, rising investment in rare disease research, a growing pipeline of novel treatment options, increasing collaborations between biotech firms and research institutes, and a rising focus on personalized medicine for metabolic disorders. Major trends in the forecast period include advancements in genetic testing technologies, advanced drug delivery systems for metabolic therapies, innovation in enzyme replacement formulations, the development of targeted gene editing tools, and advancements in newborn screening methodologies.
Claim your free report sample now:
Which Major Growth Factors Are Shaping the Isovaleric Acidemia (IVA) Treatment Market?
The increasing prevalence of metabolic disorders is expected to propel the growth of the isovaleric acidemia (IVA) treatment market going forward. Metabolic disorders are conditions that disrupt normal metabolic processes, affecting how the body converts food into energy. Common types of metabolic disorders include diabetes mellitus, hypothyroidism, hyperthyroidism, phenylketonuria (PKU), galactosemia, maple syrup urine disease (MSUD), isovaleric acidemia (IVA), Gaucher disease, Fabry disease, Wilson’s disease, and various lysosomal storage disorders. The prevalence of metabolic disorders is due to lifestyle-related factors such as poor diet and physical inactivity, which contribute to conditions like obesity and insulin resistance. Isovaleric acidemia treatment helps manage metabolic disorders by addressing the buildup of toxic substances in the body, restoring normal metabolic function, and preventing complications like neurological damage. For instance, in November 2023, according to the American Diabetes Association, a US-based non-profit organization, in 2022, around 25.5 million people in the U.S. were diagnosed with diabetes, accounting for 7.6% of the total population. Therefore, the increasing prevalence of metabolic disorders drives the growth of the isovaleric acidemia (IVA) treatment market.
What Are the Emerging Segments in the Isovaleric Acidemia (IVA) Treatment Market?
The isovaleric acidemia (iva) treatment market covered in this report is segmented –
1) By Type: Classical Isovaleric Acidemia, Moderate Isovaleric Acidemia, Non-classical Isovaleric Acidemia
2) By Treatment: Dietary Management, Enzyme Replacement Therapy, Gene Therapy, Pharmacological Treatment
3) By Route of Administration: Oral, Injectable
4)By End-user: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Classical Isovaleric Acidemia: Dietary Management, Carnitine Supplementation, Glycine Supplementation, Emergency Management, Gene Therapy (Investigational)
2) By Non-classical Isovaleric Acidemia: Observation and Preventive Care, Mild Dietary Modifications, Occasional Supplementation, Genetic Counseling and Monitoring
3) By Moderate Isovaleric Acidemia: Protein-restricted Diet, Intermittent Carnitine/Glycine Therapy, Periodic Monitoring and Supportive Care, Acute Episode Management
Which Companies Hold the Largest Share in the Isovaleric Acidemia (IVA) Treatment Market?
Major companies operating in the isovaleric acidemia (IVA) treatment market are Nestlé Health Science S.A., BioMarin Pharmaceutical Inc., GenScript Biotech Corporation, Nutricia Advanced Medical Nutrition, Rocket Pharmaceuticals Inc., REGENXBIO Inc., uniQure N.V., Vitaflo International Ltd., Orchard Therapeutics plc, Editas Medicine Inc., Cambrooke Therapeutics Inc., Recordati Rare Diseases Inc., Abbott Nutrition, Targeted Medical Pharma Inc., Solace Nutrition LLC, Nutricia Metabolics, Bluebird Bio Inc., Verve Therapeutics Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG
Get the full isovaleric acidemia (iva) treatment market report here:
Which Regions Are Driving the Most Demand in the Isovaleric Acidemia (IVA) Treatment Market?
North America was the largest region in the isovaleric acidemia (IVA) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isovaleric acidemia (IVA) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment